We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clarify Pharma PLC | AQSE:PSYC | Aquis Stock Exchange | Ordinary Share | GB00BMCD8M81 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -40.00% | 0.075 | 0.001 | 0.26 | 0.155 | 0.03 | 0.125 | 10,120,000 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMPSYC
RNS Number : 6777G
Clarify Pharma PLC
28 July 2021
28 July 2021
Clarify Pharma PLC
("Clarify Pharma" or the "Company")
Correction to the Admission Document dated 11 June 2021
Clarify Pharma (AQSE: PSYC) has identified that the statement of Directors' interests set out in the Company's Admission Document dated 11 June 2021 ("Admission Document") was incorrect. The disclosure on page 47 of the original admission document should have stated that Patrick McBride owned 20,000,000 shares of the Company via Ontario Inc. and Nicholas Lyth owned 500,000 shares of the Company. There is no change to the stated amount of total shares outstanding. The disclosure in the admission document should be read with the above correction.
-END-
About Clarify Pharma
Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing.
Clarify Pharma is working to assemble a portfolio of companies that focus on the development of psychedelic inspired medicines and experiential therapies for human clinical trials under the supervision and strict adherence to the guidelines of the United Kingdom's MHRA, Canada's Health Canada as well as similar regulatory authorities in other jurisdictions where Clarify or its Investee Companies operate.
The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.
For further information please contact:
Clarify Pharma Jon Bixby via Tancredi +44 207 887 7633 Executive Chairman ------------------------------ First Sentinel ------------------------------ Corporate Adviser Brian Stockbridge +44 7876 888 011 ------------------------------ Tennyson Securities ------------------------------ Corporate Broker Peter Krens +44 207 186 9030 ------------------------------ Tancredi Intelligent Communication ------------------------------ Media Relations Catrina Daly Emma Hodges +44 7727 153 868 Salamander Davoudi +44 7861 995 628 clarifypharma@tancredigroup.com +44 7957 549 906 ------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXFFFSLDIIDFIL
(END) Dow Jones Newswires
July 28, 2021 02:00 ET (06:00 GMT)
1 Year Clarify Pharma Chart |
1 Month Clarify Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions